Our first ZS portfolio and business development quarterly webinar of the year offered key insights for pharma leaders executing their 2024 strategies. This report, based on that same data, highlights:
- New drug success: Launches and revenue generated by new molecular entities approved in 2023
- Industry growth drivers: Which types of organizations are fueling the industry’s overall valuation increase
- Funding innovation: New funding avenues pharmaceutical companies are exploring
- Clinical trial trends: The reasons behind the decline in clinical trial volume
- Investment hotspots: Therapeutic areas attracting the most deal activity
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
